Alkermes Plc (ALKS) Stock AnalysisALKSStock AnalysisAlkermes Plc

Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alkermes Plc is currently trading at $47.41, which is below several analyst price targets, including $61 from JPMorgan and $65 from Piper Sandler. However, the stock has a low RSI of 29.035, indicating it may be oversold, but the recent earnings report showed a GAAP EPS of $0.00, reflecting no profit. The company's forward P/E ratio is high at 133.33, suggesting it may be overvalued at this price. Given the mixed signals from analysts and the lack of profitability, it is prudent to hold rather than buy at this time.

12 analysts cover ALKS: 5 rate it Buy, 7 Hold and 0 Sell. The average price target is 46.20.